Navigation Links
Memory Pharmaceuticals Reports First Quarter 2008 Financial Results
Date:5/14/2008

eriod in 2007. The change included $3.1 million in increased costs related to the development of R3487/MEM 3454 and R4996/MEM 63908, and a $0.9 million increase related to manufacturing and preclinical costs associated with the 5-HT6 antagonist program, offset by a $3.4 million decrease in costs associated with the clinical development of MEM 1003.

General and administrative expenses for the quarter ended March 31, 2008 were $2.9 million, compared to $2.3 million for the same period in 2007. The change included an increase of $0.2 million in personnel and personnel-related costs, a $0.2 million increase in legal fees, and a $0.2 million increase in outside services.

At March 31, 2008, the Company had cash, cash equivalents and marketable securities of approximately $27.5 million, compared to $38.2 million at the end of 2007. The Company continues to expect that its existing cash, cash equivalents, and marketable securities, together with payments expected to be made under its collaboration agreements, should be sufficient to fund operating expenses, scheduled debt obligations and capital equipment requirements into the first half of 2009.

First Quarter Highlights and Recent Developments

-- Roche Opt-in for R3487/MEM 3454. In May, Roche exercised its option to

license R3487/MEM 3454, Memory Pharmaceuticals' lead nicotinic alpha-7

receptor agonist, for further development and commercialization in

psychiatric and neurological disorders. The option exercise triggers a

$6.0 million milestone payment and entitles Memory Pharmaceuticals to

future payments upon the achievement of additional milestones and

royalties on product sales, including a $17.0 million milestone payment

upon the completion of the ongoing Phase 2a study in cognitive

impairment associated with schizophrenia. In addition, Memory

Pharmaceuticals retains an option to co-promote R3487/MEM 345
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Memory Pharmaceuticals to Announce First Quarter 2008 Results on Wednesday, May 14, 2008
2. Memory in artificial atoms
3. Memory Pharmaceuticals Receives Nasdaq Notification
4. Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
5. Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
6. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
7. Memory Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
9. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
10. Memory Pharmaceuticals to Announce Third Quarter Results on Thursday, November 8, 2007
11. ASU researchers improve memory devices using nanotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... WA , Sept. 17, 2014 /PRNewswire/ - Oncothyreon ... it intends to offer and sell shares of its ... separate but concurrent underwritten public offerings.  The Series A ... of Oncothyreon Common Stock, provided that conversion will be ... affiliates would beneficially own more than 4.99% of the ...
(Date:9/17/2014)... A biodegradable polymer can be ... bacteria, fungi, and algae into smaller units (monomers) ... compounds, carbon dioxide, and humus in a specified ... improved costs, biodegradable polymers are proving to be ... conventional polymers. Primary factors that are responsible for ...
(Date:9/17/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... cost and predictability of non-adherence in type 2 diabetes ... the European Association for the Study of Diabetes (EASD). ... Ph.D., of Analysis Group, Inc. presented data from the ... to characterize the prevalence of non-adherence and serial non-adherence, ...
(Date:9/17/2014)... , Sept. 17, 2014 RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today announced that it has been granted ... Trademark Office on its unique delivery system for ... to phagocytic cells for the treatment of diseases ...
Breaking Biology Technology:Oncothyreon Announces Proposed Public Offerings 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4
... CHICAGO, Sept. 28, 2011 GTL Resources PLC (AIM: GTL) ... on the state of its business. Julia Henderson, the non-executive ... trends and reaffirmed the current business approach: ... with expectations and in the six month period ending September ...
... Managing RA: The Strong Woman,s Approach ... women living with rheumatoid arthritis (RA), launched today at HealthyWomen.org. ... are two to three times more likely to develop the ... provides practical solutions and exercise advice specifically designed to ...
... delivery systems, solar cells, industrial catalysts and video displays ... possess two chemically distinct sides. These particles are named ... chemical faces allow them to form novel structures and ... of Janus particles down to a few nanometers in ...
Cached Biology Technology:The Strong Woman's Approach to Managing Rheumatoid Arthritis 2The Strong Woman's Approach to Managing Rheumatoid Arthritis 3The Strong Woman's Approach to Managing Rheumatoid Arthritis 4New technique maps twin faces of smallest Janus nanoparticles 2
(Date:9/17/2014)... from the Copenhagen Centre for Social Evolution and Yale ... that birth weight and -length can partially predict the ... as autism and schizophrenia later in life. The study ... subsequent hospital diagnoses for up to 30 years, and ... study is published today in the Proceedings of ...
(Date:9/17/2014)... 2014 Researchers at UTSouthwestern Medical Center have found ... apolipoprotein E, called apoE3, helps repair the lining of ... not get the benefit of this repair, putting them ... that we have identified one mechanism by which apoE3 ... variant, apoE4, is detrimental," said Dr. Philip Shaul ...
(Date:9/17/2014)... a great deal about complex social behavior by studying ... to teach too. , With their unusually large brains ... live in a complex social environment---not merely in a ... ants, but in a dynamic setting of alliances and ... mammals: dolphins, whales, primates, and social carnivores, like hyenas ...
Breaking Biology News(10 mins):Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Protein variant may boost cardiovascular risk by hindering blood vessel repair 2Being social: Learning from the behavior of birds 2
... over recent years have established a foothold in understanding ... it might contribute to aging and lifespan are not ... p53 function in fruit flies show new evidence that ... against tumor formation, normal levels of p53 activity--at least ...
... be published in the January 2006 issue of Nature ... Memorial Sloan-Kettering Cancer Center have devised a novel strategy ... to genetically reverse sickle cell disease (SCD) in human ... way to genetically correct this debilitating blood disease using ...
... years, biologists have searched for evolutionary clues to this ... play in the evolution of the postreproductive lifespan? ... years, postreproductive females should contribute to the fitness of ... effect." Though many mammals, including lions and baboons, rear ...
Cached Biology News:New clues to the dark side of a key anti-tumor guardian 2Sickle cell disease corrected in human models using stem cell-based gene therapy 2Getting an evolutionary handle on life after reproduction 2
... for biological safety labs (BSL) and ... Class 10/ISO 3) and easy sterilization. ... surfaces that are easy to wipe ... simplify cleaning. Unique double-wall panel design ...
... cleanroom for biological safety labs (BSL) ... (to Class 10/ISO 3) and easy ... ultra-smooth surfaces that are easy to ... corners simplify cleaning. Unique double-wall panel ...
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation of endotoxins for research purposes. sensitivity 0.05-0.1 EU/mL...
... testing at various temperatures, this chamber ... a clean heating unit to maintain ... 140F. Transparent panels allow full visibility, ... access to the work area. Includes ...
Biology Products: